The Hanson Wade Group’s 4th Mitochondrial Dysfunction Drug Development Summit kicks off this month from November 19th – 21st in Boston, MA. On November 20, Pretzel’s COO Baruch Harris is participating in a panel titled “Translating Modality into Value for Patients to Establish Clearly Defined Clinical Objectives” panel and presenting “Modulating Novel Mitochondrial Targets to Treat Mitochondrial Disease, Diseases of Aging & Metabolism”. We are looking forward to connecting with fellow industry experts who are part of the crucial mission to push forward innovation and expand novel therapeutic opportunities for mitochondria-targeting approaches ? Learn more about the summit here: https://bit.ly/3YsEaJZ ? #MitochondrialDisease #MitochondrialDiseases ?
Pretzel Therapeutics
生物技术研究
Boston，MA 3,224 位关注者
Welcome to a new era in mitochondrial therapeutics
关于我们
Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.
- 网站
-
https://www.pretzeltx.com
Pretzel Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston，MA
- 类型
- 私人持股
地点
-
主要
获取路线
US，MA，Boston
Pretzel Therapeutics员工
动态
-
Pretzel is proud to announce that one of our Scientific Advisory Board members, Matthew Vander Heiden MD, PhD, M.D., Ph.D., was recently elected into the National Academy of Medicine! The academy recognized his contributions towards the development of approved therapies for both cancer and anemia, as well as thought leadership on demonstrating metabolic phenotypes’ relations to disease pathogenesis. Dr. Vander Heiden serves as the director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, a Lester Wolfe Professor of Molecular Biology, and a member of the Broad Institute of MIT and Harvard. Read more on his achievement here: https://lnkd.in/ehtAZGn5 #NAMmtg
-
-
The Hanson Wade Group’s 4th Mitochondrial Dysfunction Drug Development Summit kicks off this month from November 19th – 21st in Boston, MA. On November 20, Pretzel’s COO Baruch Harris is participating in a panel titled “Translating Modality into Value for Patients to Establish Clearly Defined Clinical Objectives” panel and presenting “Modulating Novel Mitochondrial Targets to Treat Mitochondrial Disease, Diseases of Aging & Metabolism”. We are looking forward to connecting with fellow industry experts who are part of the crucial mission to push forward innovation and expand novel therapeutic opportunities for mitochondria-targeting approaches ? Learn more about the summit here: https://bit.ly/3YsEaJZ ? #MitochondrialDisease #MitochondrialDiseases ?
-
-
Thank you to Angelini Ventures for bringing together industry experts from all areas of healthcare for last month’s summit. Pretzel’s COO Baruch Harris joined the variety of key industry voices for comprehensive discussions and presentations throughout the busy event. Check out this video from Terroir Films, which does a great job summarizing this fantastic inaugural summit. We are looking forward to future events!
One month after our first Angelini Ventures Healthcare Summit, we're excited to share this aftermovie that captures the spirit of innovation and collaboration that defined the event! This video isn't just a celebration?of a successful event that brought together 100 key players in healthcare, including investors, experts, portfolio companies, and colleagues from Angelini Industries and Angelini Pharma. It reflects our two-year journey at Angelini Ventures (October 19th marks our official second anniversary! ??) and our core belief: innovation thrives on relationships. We extend our heartfelt thanks to all participants, with special gratitude to the speakers who shared their valuable perspectives in this video: thank you Jill Schiaparelli, MBA (Avation Medical), Baruch Harris (Pretzel Therapeutics), Suman Rao, PhD (Lumira Ventures), Shriram Raghunathan, Ph.D (Noctrix Health, Inc.). Here's to many more years of collaborative progress in healthcare! Video credits ??: Terroir Films
-
Meet us in Stockholm during #BIOEurope, taking place Nov 4-6! Our COO?Baruch Harris?will be onsite for BIOEurope’s 30th anniversary to meet with global business leaders and industry experts in the biotech and pharma field. Reach out to our team if you’re interested in connecting with Baruch at the conference to hear more about Pretzel. #MitochondrialDisease
-
-
Today marks the beginning of World Mitochondrial Disease Week. A time to raise awareness of #MitochondrialDisease through education, fundraising, and advocacy activities. Together we can #IlluminateTomorrow by increasing awareness and showing our support for the patient communities and healthcare professionals working to improve the lives of all those affected. Learn how you can help: https://bit.ly/3XEnjn0 #WorldMitoWeek2024 #WorldMitoWeek #IlluminateTomorrow #MitochondrialDiseases #IlluminateTomorrow
-
-
We are excited to share the news that?one of our founders, Nils-Goran Larsson, MD, PhD, published a seminal study this week in Nature Metabolism?on a potential new approach for treating obesity and metabolic diseases. Larsson and his team at the Department of Medical Biochemistry and Biophysics at?Karolinska Institutet?found that by inhibiting transcription in mitochondria (the "powerhouse of the cell") with small molecules in a mouse diet-induced obesity model – they could alter liver metabolism directly, encouraging the body to burn fat without the adverse effects on muscle mass as seen with GLP-1 drugs. Overcoming this issue is critical for developing the next generation of weight loss medications. While this research is still in its early days, we are encouraged to continue seeing the potential promise our approach of targeting mitochondria can bring to helping patients.? ? To read the full study, "Inhibition of mammalian mtDNA transcription acts paradoxically to reverse diet-induced hepatosteatosis and obesity" follow this link: https://lnkd.in/ghtJ8Pzt #obesity #obesityresearch #metabolicdisease
-
-
Read about how Pretzel is bridging innovation and collaboration to help patients with mitochondrial disease:
Meet our community. In September this year, Sweden and US-based biotech start-up company Pretzel Therapeutics moved into its new office and lab space at GoCo?House. Read the full article from when we sat down with Pretzel’s Senior Vice President and Head of Biology, Thomas A. Keating, to talk about Pretzel’s work on rare mitochondrial diseases, novel biology, and what is needed for successful?collaboration. #collaboration #innovation #gocohic #lifescience